Prahara Yuri and Grace Wangge and Fatan Abshari and Adistira I.T.W.H Satjakoesoemah and Noor R. Perdana and Candra D.K. Wijaya and Christiano Tansol and Aaron Tigor and Ferry Safriadi and Dhirajaya D. Kadar and Syah M. Warli and Sungsang Rochadi and Danarto and Lukman Hakim, NIDN. 0009087302 and Wahjoe Djatisoesanto, NIDN. 8826900016 and Sunarjo Hardjowijoto, NIDN. 9900981294 and Chaidir A. Mochtar and Rainy Umbas and Agus Rizal A.H. Hamid (2015) Indonesian Prostate Cancer Risk Calculator (IPCRC): An application for Predicting Prostate Cancer Risk (a Multicenter Study). Acta Medica Indonesiana, 47 (02). pp. 95-103. ISSN 220125-9326

	Text (Artikel) Indonesian Prostate Cancer Risk Calculator (IPCRC) An application for Predicting Prostate Cancer Risk (a Multicenter Study).pdf Download (514kB)
	Text (Peer Review) Artikel Indonesian Prostate Cancer Risk Calculator.pdf Download (2MB)
	Text (Similarity) Indonesian Prostate Cancer Risk Calculator (IPCRC) An application for Predicting Prostate Cancer Risk (a Multicenter Study)_compressed.pdf Download (2MB)

Abstract

Aim: to develop a prediction risk model of prostate cancer based on Indonesia population. Methods: we included all benign prostate hyperthrophy (BPH) and PCa patients who had prostate biopsy and prostatectomy between January 2009 and December 2013 from 5 urology centers in Indonesia. The relationship between the possibility of PCa with the following variables including: age; PSA level, prostate volume (by transabdominal ultrasound or transrectal ultrasound) and digital rectal examination (DRE) finding. We calculated a predictive scoring equation to predict the possibility of PCa using chi-square analysis, Kolmogorov-Smirnov test, multiple logistic regression and ROC curve. Then, we designed an application for predicting prostate cancer risk called Indonesian Prostate Cancer Risk Calculator (IPCRC). Results: there were 784 PCa and 1173 BPH patients were used for developing the risk calculator in our study. The mean ages, PSA and prostate volume are 66.9±8.1 years old; 72.4±248.9 ng/ml and 49.6±28.2 ml, respectively. Abnormal DRE was found in 637 PCa and 56 BPH. We included age, PSA level, abnormal DRE finding (all showed significant p<0.05 in univariate model). Additionally, although not significant, we included prostate volume (p=0.157) due to its clinical importance. The corrected ROC analysis showed AUC 0.935, sensitivity of 90.1% and specificity 80% in predicting the prostate cancer in our population. Conclusion: we have developed the Indonesian Prostate Cancer Risk Calculator which includes age, PSA, DRE, and prostate volume as its variables. Future prospective study to validate the risk calculator is needed.

Actions (login required)

View Item